InstaDeep

InstaDeep's valuation is not publicly disclosed.

Investor information for InstaDeep is not publicly available at this time.

No public funding round data is currently available for InstaDeep.

InstaDeep has approximately 100-500 employees.

InstaDeep built AI decision-making systems for complex industrial and enterprise applications, combining deep reinforcement learning, graph neural networks, and large-scale optimisation techniques to address routing, scheduling, and resource allocation problems across logistics, life sciences, and infrastructure sectors. The company was founded in Tunis and grew its engineering hub in London, operating at the intersection of fundamental AI research and commercial deployment.\n\nThe company raised approximately $100 million prior to its acquisition by BioNTech, the mRNA therapeutics company, in January 2023 for approximately $680 million. The acquisition gave BioNTech an AI engineering capability to apply to drug design, clinical trial optimisation, and mRNA sequence design, with InstaDeep team integrating into BioNTech AI capabilities. Prior to the BioNTech deal, InstaDeep had research partnerships with Google DeepMind and applied its reinforcement learning expertise to protein structure prediction and biological sequence optimisation.\n\nInstaDeep operated in the applied deep reinforcement learning market, a niche segment of enterprise AI that requires combining algorithmic research with domain-specific engineering. The BioNTech acquisition represented one of the largest exits for an African-founded technology company and validated the intersection of reinforcement learning with pharmaceutical AI as a high-value application area. The company mission to bridge academic AI research and industrial deployment aligned naturally with BioNTech strategy of building internal AI capabilities to accelerate its mRNA medicine pipeline.